Results 31 to 40 of about 4,245 (206)

Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study

European Journal of Hybrid Imaging, 2021
Background Early [68Ga]Ga-DOTA-TOC PET/CT imaging after peptide receptor radionuclide therapy (PRRT) in neuroendocrine neoplasm patients is often used as a prognosticator for survival, but lacks validity.
Sander C. Ebbers, Muriël Heimgartner, Maarten W. Barentsz, Rachel S. van Leeuwaarde, Mark J. C. van Treijen, Marnix M. E. G. Lam, Arthur J. A. T. Braat   +6 more
doaj   +1 more source

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors

Frontiers in Oncology, 2021
IntroductionNeuroendocrine neoplasms including neuroendocrine tumors (NETs) are often diagnosed as primary disseminated or inoperable. In those cases, systemic extensive therapy is necessary, but radical treatment is unlikely.
Marta Opalińska, Anna Sowa-Staszczak, Anna Grochowska, Helena Olearska, Alicja Hubalewska-Dydejczyk   +4 more
doaj   +1 more source

Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report

Frontiers in Endocrinology, 2021
IntroductionPrimary cardiac paragangliomas are rare tumors. Metastatic disease is even rarer. Surgical management is technically challenging, and sometimes even impossible.
Alexis Huot Daneault, Mélanie Desaulniers, Jean-Mathieu Beauregard, Alexis Beaulieu, Frédéric Arsenault, Geneviève April, Éric Turcotte, François-Alexandre Buteau   +7 more
doaj   +1 more source

Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms [PDF]

, 2018
Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin receptor expressing neuroendocrine neoplasms has shown promising results in clinical trials and a recently published phase III study.In our center, 2294 patients were screened ...
Baum, Richard P., Hommann, Merten, Robiller, Franz C., Dieter Hörsch, Aviral Singh, Dirk Mueller, Lambin, Philippe, Richard P. Baum, Mueller, Dirk, Daniel Kaemmerer, Arthur Jochems, Jochems, Arthur, Holger Franz, Kaemmerer, Daniel, Karin Niepsch, Franz C. Robiller, Kulkarni, Harshad R., Philippe Lambin, Vikas Prasad, Prasad, Vikas, Holger, Franz, Merten Hommann, Harshad R. Kulkarni, Singh, Aviral, Horsch, Dieter, Niepsch, Karin   +25 more
core   +1 more source

Year in Review 2018 by the Brazilian Gastrointestinal Tumors Group: Neuroendocrine Tumors

Brazilian Journal of Oncology, 2018
Neuroendocrine tumors (NET) constitute a heterogeneous group of neoplasms with variable prognoses and clinical presentations. Therefore their therapeutic management is challenging, involving a real multidisciplinary approach composed of medical ...
Duilio R. Rocha, Juliana F. Rego, Rachel P. Riechelmann   +2 more
doaj   +1 more source

A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients [PDF]

, 2022
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]-octreotate (177Lu-DOTATATE) has become an established second- or third-line treatment option for patients with somatostatin receptor (SSTR)-positive advanced well-differentiated ...
Morticia N. Becx, Brabander, Tessa, Becx, Morticia N., Minczeles, Noémie S., Hofland, Johannes, Johannes Hofland, Tessa Brabander, Noémie S. Minczeles, de Herder, Wouter W., Nonnekens, Julie; id_orcid, Julie Nonnekens, Wouter W. de Herder, Nonnekens, Julie   +12 more
core   +1 more source

Treatment of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms by Radionuclide Therapy: Practice and Experience

Xiehe Yixue Zazhi, 2022
Peptide receptor radionuclide therapy (PRRT) is one of the advanced therapies for neuroendocrine neoplasms (NENs), which can relieve the symptoms and improve the quality of life of patients with NENs with good tolerance to the treatment.However, since ...
LEI Lei, DU Tao, OU Xia, ZHU Yan, ZHANG Yu, ZHANG Wei   +5 more
doaj   +1 more source

Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy

Endocrinology, Diabetes & Metabolism Case Reports, 2022
Acanthosis nigricans (AN) is a common dermatosis associated with hyperinsulinemia and insulin resistance. However, AN has been rarely reported in patients with insulinoma, a state of persistent hyperinsulinemia. We present a case of metastatic insulinoma,
Jenny S W Yun, Chris McCormack, Michelle Goh, Cherie Chiang   +3 more
doaj   +1 more source

Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT)

Blood, 2020
Background. Clonal hematopoiesis (CH) prevalence increases with age. Elderly (>70 years) healthy individuals have a 10% incidence of CH. Cancer cohorts are at increased risk of harboring CH mutations (~25%). Specific tumor types such as thyroid, ovarian, and bladder, have previously been shown to be at the highest risk of CH due to increased ...
Abhay Singh, Matthew Gravina, Rutaba Tajammal, Annmarie Nowak, Renuka Iyer, Mark G. Faber, LunBiao Yan, Duane C. Hassane, Monica L. Guzman, Nuria Mencia-Trinchant, Eunice S. Wang, Swapna Thota   +11 more
openaire   +1 more source

Peptide Receptor Radionuclide Therapy in Thyroid Cancer

Frontiers in Endocrinology, 2022
The treatment options that are currently available for management of metastatic, progressive radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary thyroid cancers (MTCs) are limited.
Sriram Gubbi, Christian A. Koch, Christian A. Koch, Joanna Klubo-Gwiezdzinska   +3 more
doaj   +1 more source